First Scientific communication: one article submitted or results from I-MOVE+ influenza vaccines presented in an International Scientific Conference.

At least one scientific article presenting the results of the influenza VE and impact I-MOVE+ studies will be submitted at the end of the season to an open source journal. An abstract will be submitted to the ESCAIDE conference or to any other relevant conference.